HAMPTON, N.J., Nov. 05, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data from the Company’s Phase 1b study of barzolvolimab in prurigo nodularis (PN).

Orlando, Florida--(Newsfile Corp. - October 6, 2023) - PN Medical, a cardiopulmonary device manufacturer developing combined respiratory muscle training (cRMT) devices, today announced that it has ...

TRuE-PN1 Study: 44.6% of PN patients using ruxolitinib cream saw ≥4-point WI-NRS4 improvement at Week 12 vs. 20.6% with vehicle control. TRuE-PN2 Study: The primary endpoint missed statistical ...

The government should publish the carrying capacity study on which the decision to create a pre-booking system for Comino was based, the Nationalist Party said on Friday. “The fact that the government ...